GLP-1 Therapies Newsletter
Issue #7October 20, 20257 studies

GLP-1 drugs linked to sharply lower rates of alcohol addiction

GLP-1 drugs linked to sharply lower rates of alcohol addiction

Monday, October 20th GLP-1 Therapies Newsletter Issue #7

The GLP-1 revolution is expanding far beyond diabetes and weight loss. This week's research reveals these medications might help treat alcohol addiction, work as pills instead of injections, and even improve conditions from inflammatory bowel disease to brain pressure disorders.

🍷 GLP-1 Drugs Cut Alcohol Addiction Risk by Half

Researchers analyzed over 120 million patient records and found something unexpected: people with diabetes taking certain GLP-1 medications were much less likely to develop alcohol use disorders.

  • Tirzepatide (Mounjaro) reduced new alcohol addiction diagnoses by 53% compared to standard diabetes drugs

  • Semaglutide (Ozempic) cut the risk by 32% over an 18-month period

  • The effect was strongest with tirzepatide, which was 53% more protective than liraglutide

Why this matters: These findings suggest GLP-1 drugs might work on the same brain pathways involved in addiction, not just appetite. If confirmed in clinical trials, it could open an entirely new treatment avenue for the 29 million Americans with alcohol use disorders.

🥉 Top 5% journal 🔗 Diabetes, Obesity and Metabolism 🗓️ Oct 8

Key Findings

💊 Oral GLP-1 Pills Work Almost as Well as Injections

Two major trials tested pill versions of GLP-1 drugs, potentially solving the injection barrier that keeps many people from treatment. Oral semaglutide (25mg) helped 307 adults lose an average of 13.6% of their body weight over 64 weeks, with 63% losing at least 10%. A competing oral drug, orforglipron, achieved 11.2% weight loss in 3,127 people over 72 weeks, with 54.6% hitting the 10% threshold.

💡 Oral GLP-1 drugs could dramatically expand access by eliminating the need for weekly injections.

🧠 Brain Pressure Disorder Improves with GLP-1 Treatment

Nine studies involving patients with idiopathic intracranial hypertension (a condition causing dangerous brain pressure) found that GLP-1 drugs consistently reduced headaches, lowered brain pressure, and decreased the need for surgery or other medications. One small trial showed exenatide lowered brain pressure within hours of administration.

💡 GLP-1 drugs might treat neurological conditions beyond their known metabolic effects.
🥉 Top 5% journal 🔗 Journal of Headache and Pain 🗓️ Oct 7

🏥 Veterans Study Shows All GLP-1 Drugs Protect Hearts and Kidneys Equally

A massive study of 21,790 veterans with diabetes found that liraglutide, semaglutide, and dulaglutide all provided similar protection against kidney failure and heart problems. However, liraglutide users had lower death rates compared to dulaglutide users (31% lower risk) and possibly semaglutide users.

💡 When it comes to protecting vital organs, the choice between GLP-1 drugs may matter less than just getting on one.
🥈 Top 2% journal 🔗 JAMA Network Open 🗓️ Oct 13

🔬 Next-Generation GLP-1 Drugs Target Multiple Hormones

Scientists are developing more powerful versions that hit multiple hormone targets simultaneously. Triple-action drugs like retatrutide target GIP, GLP-1, and glucagon receptors for amplified weight loss. Other combinations include cagrilintide + semaglutide and new oral small-molecule drugs resistant to breakdown.

💡 The current GLP-1 drugs may be just the beginning of a new era in metabolic medicine.
🥇 Top 1% journal 🔗 Endocrine Reviews 🗓️ Oct 7

🦠 IBD Patients See Reduced Surgery Risk on GLP-1 Drugs

Analysis of 16,242 inflammatory bowel disease patients taking GLP-1 medications showed a 54% lower risk of needing surgery and reduced hospitalizations. The benefits were strongest in obese patients (BMI ≥30), with semaglutide, liraglutide, and tirzepatide all achieving 9-12 kg weight loss after 3 months.

💡 GLP-1 drugs might help IBD patients avoid surgery by addressing the obesity that worsens their condition.
🥉 Top 5% journal 🔗 Journal of Crohn's and Colitis 🗓️ Oct 10

🔥 Real-World Data Confirms Tirzepatide Beats Semaglutide

Healthcare records from 21,404 matched patients showed tirzepatide consistently outperformed injectable semaglutide. Among treatment-naive patients, tirzepatide reduced A1C by 1.3% vs 0.9% for semaglutide, and achieved 10.2 kg vs 6.1 kg weight loss over 12 months. Even patients switching from other GLP-1 drugs did better on tirzepatide.

💡 The dual-hormone approach of tirzepatide appears to provide meaningful advantages over single-hormone GLP-1 drugs.
Top 20% journal 🔗 Diabetes Therapy 🗓️ Oct 9

Implications

GLP-1 drugs are proving to be far more than diabetes medications—they're emerging as multi-system therapies that could reshape treatment for addiction, brain disorders, inflammatory diseases, and obesity. With oral formulations removing injection barriers and next-generation multi-hormone drugs in development, we may be witnessing the early stages of a medical revolution that extends well beyond metabolic health.

Studies in this issue

Primary sources used for this newsletter.

  1. Comparing the effectiveness of GLP-1 and combined GLP-1/GIP receptor drugs in preventing alcohol use disorders
    main storyDiabetes, obesity & metabolism2025-10-08PMID 41058240
  2. Tirzepatide versus Semaglutide effects on blood sugar and weight in people with type 2 diabetes
    key findingDiabetes therapy : research, treatment and education of diabetes and related disorders2025-10-09PMID 41066072
  3. Use of diabetes drugs that affect appetite hormones in unexplained high brain pressure: a systematic review
    key findingThe journal of headache and pain2025-10-07PMID 41057780
  4. Oral GLP-1 treatment becomes a new option for obesity
    key findingCardiovascular diabetology. Endocrinology reports2025-10-07PMID 41053816
  5. Comparing Liraglutide, Semaglutide, and Dulaglutide in Veterans with Type 2 Diabetes
    key findingJAMA network open2025-10-13PMID 41082229
  6. New GLP-1 Treatments for Diabetes and Obesity
    key findingEndocrine reviews2025-10-07PMID 41054801
  7. Glucagon-like peptide 1 receptor agonists and health outcomes in inflammatory bowel disease
    key findingJournal of Crohn's & colitis2025-10-10PMID 41071055

Continue reading

All GLP-1 Therapies issues